Bruker Corporation (BRKR)
NASDAQ: BRKR · Real-Time Price · USD
42.88
-1.28 (-2.90%)
At close: May 15, 2026, 4:00 PM EDT
42.90
+0.02 (0.05%)
After-hours: May 15, 2026, 5:57 PM EDT
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
United States Revenue | 895.80M | 891.30M | 938.50M | ||||||||||||
United States Revenue Growth | 0.51% | -5.03% | 20.68% | ||||||||||||
Germany Revenue | 298.60M | 297.00M | 310.70M | ||||||||||||
Germany Revenue Growth | 0.54% | -4.41% | 10.37% | ||||||||||||
Europe excluding Germany Revenue | 985.00M | 950.20M | 873.00M | ||||||||||||
Europe excluding Germany Revenue Growth | 3.66% | 8.84% | 24.77% | ||||||||||||
China Revenue | 448.60M | 475.80M | 471.20M | ||||||||||||
China Revenue Growth | -5.72% | 0.98% | -10.77% | ||||||||||||
Rest of Asia Pacific Revenue | 555.90M | 552.60M | 518.50M | ||||||||||||
Rest of Asia Pacific Revenue Growth | 0.60% | 6.58% | 12.50% | ||||||||||||
Total Asia Pacific Revenue | 1.00B | 1.03B | 989.70M | ||||||||||||
Total Asia Pacific Revenue Growth | -2.32% | 3.91% | 0.07% | ||||||||||||
Other Countries Revenue | 274.60M | 269.60M | 254.50M | ||||||||||||
Other Countries Revenue Growth | 1.85% | 5.93% | 17.50% | ||||||||||||
Revenue (Total) | 3.46B | 3.44B | 3.37B | ||||||||||||
Revenue (Total) Growth | 0.64% | 2.08% | 13.56% |
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
BSI BioSpin Revenue | 868.50M | 878.80M | 905.70M | ||||||||||||
BSI BioSpin Revenue Growth | -1.17% | -2.97% | 13.43% | ||||||||||||
BSI CALID Revenue | 1.25B | 1.21B | 1.09B | ||||||||||||
BSI CALID Revenue Growth | 2.99% | 10.67% | 13.86% | ||||||||||||
BSI Life Science Revenue | 2.11B | 2.09B | 2.00B | ||||||||||||
BSI Life Science Revenue Growth | 1.24% | 4.49% | 13.66% | ||||||||||||
BSI Nano Revenue | 1.07B | 1.08B | 1.10B | ||||||||||||
BSI Nano Revenue Growth | -0.98% | -1.27% | 16.61% | ||||||||||||
Total BSI Revenue | 3.19B | 3.17B | 3.10B | ||||||||||||
Total BSI Revenue Growth | 0.48% | 2.45% | 14.69% | ||||||||||||
BEST Revenue | 278.50M | 270.90M | 283.00M | ||||||||||||
BEST Revenue Growth | 2.80% | -4.28% | 0.82% | ||||||||||||
Eliminations from Revenue | -8.60M | -7.70M | -14.10M | ||||||||||||
Revenue (Total) | 3.46B | 3.44B | 3.37B | ||||||||||||
Revenue (Total) Growth | 0.64% | 2.08% | 13.56% |
EBIT
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
BSI BioSpin Operating Income | 96.60M | 104.30M | 157.80M | ||||||||||||
BSI BioSpin Operating Income Growth | -7.38% | -33.90% | -19.45% | ||||||||||||
BSI CALID Operating Income | 153.80M | 153.30M | 180.00M | ||||||||||||
BSI CALID Operating Income Growth | 0.33% | -14.83% | -14.00% | ||||||||||||
BSI Life Science Operating Income | 250.40M | 257.60M | 337.80M | ||||||||||||
BSI Life Science Operating Income Growth | -2.79% | -23.74% | -16.63% | ||||||||||||
BSI Nano Operating Income | -86.60M | -71.80M | 2.30M | ||||||||||||
BSI Nano Operating Income Growth | - | - | -97.89% | ||||||||||||
Corporate, Eliminations and Other Operating Income | -137.20M | -137.00M | -121.90M | ||||||||||||
Total BSI Operating Income | 26.60M | 48.80M | 218.20M | ||||||||||||
Total BSI Operating Income Growth | -45.49% | -77.64% | -46.07% | ||||||||||||
BEST Operating Income | 20.00M | 19.40M | 34.90M | ||||||||||||
BEST Operating Income Growth | 3.09% | -44.41% | 8.05% | ||||||||||||
Operating Income (Other) | -26.60M | -48.80M | -218.20M | ||||||||||||
Operating Income (Total) | 46.60M | 68.20M | 253.10M | ||||||||||||
Operating Income (Total) Growth | -31.67% | -73.05% | -42.07% |
Capital Expenditures
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
BSI BioSpin Capital Expenditures | 11.40M | 22.80M | ||||||||||||
BSI BioSpin Capital Expenditures Growth | -50.00% | -4.60% | ||||||||||||
BSI CALID Capital Expenditures | 25.30M | 34.10M | ||||||||||||
BSI CALID Capital Expenditures Growth | -25.81% | 8.60% | ||||||||||||
BSI Life Science Capital Expenditures | 36.70M | 56.90M | ||||||||||||
BSI Life Science Capital Expenditures Growth | -35.50% | 2.89% | ||||||||||||
BSI Nano Capital Expenditures | 36.50M | 19.30M | ||||||||||||
BSI Nano Capital Expenditures Growth | 89.12% | 38.85% | ||||||||||||
Corporate Capital Expenditures | 16.00M | 14.80M | ||||||||||||
Corporate Capital Expenditures Growth | 8.11% | 45.10% | ||||||||||||
Total BSI Capital Expenditures | 89.20M | 91.00M | ||||||||||||
Total BSI Capital Expenditures Growth | -1.98% | 14.61% | ||||||||||||
BEST Capital Expenditures | 13.80M | 24.30M | ||||||||||||
BEST Capital Expenditures Growth | -43.21% | -11.64% |
Updated May 7, 2026. Data Source: Fiscal.ai.